Pacific Biosciences PACB

$2.14 +0.18 (9.18%)

Valuation

Market cap
571,929,000
Revenue TTM
$160,010,000
Net income TTM
$-546,380,000
PE ratio
0.00
Forward PE
—
Profit margin
-341.47%
Debt to equity
0.00

Trading

Volume
13,492,023
Avg volume
12,011,344
Day's range
$1.92 – $2.19
Shares out
310,831,000
Stochastic %K
26%
Beta
2.19
Analysts
Sell
Price target
$2.14

Price

Company profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library forma...

Show more

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Industry
Medical Devices
Sector
Healthcare
Phone
650 521 8000
Website
https://www.pacb.com
Address
1305 O’Brien Drive, Menlo Park, United States

Latest news

Stocktwits

LMSS Oct 21, 9:28 PM
$PACB Great partnerships Huge future Undervalued $25
0 replies
DeaneOfGreen Oct 21, 7:31 PM
$PACB this aged BEAUTIFULLY
1 replies
MrScottTwits Oct 21, 6:22 PM 0 replies
Razor_Ramon Oct 21, 6:06 PM
$PACB 2nd leg up incoming.
0 replies
M777tiol Oct 21, 5:11 PM 0 replies
DomLuminous Oct 21, 4:04 PM
$PACB its powering up again!!
0 replies
Razor_Ramon Oct 21, 3:37 PM
$PACB Accumulatiocione.! It looks like @MingLin spoke too soon and put foot in mouth after been in ass.
1 replies
AnomalyDetective Oct 21, 3:30 PM
💥 $RCEL still going strong from July breakout up +231% and may be nearing a peak soon. 🔍Watch for prior MDA biotechs $PACB and capital market stocks like $NAKA and others to breakout in Q4 as earliest sign of the risk-on in the October breakout cycle: https://seekingalpha.com/article/4953356?gt=f76ecfa91a7507f4 ⚠️ Market Gauges still negative but off the worst levels since November 2025 in potential bottoming signal. Credit: http://vmbreakouts.com @vmbreakouts
0 replies